Literature DB >> 3808962

Radioimmunodetection of malignant melanoma with the 225.28S monoclonal antibody to HMW-MAA.

G L Buraggi.   

Abstract

A review of the studies on the use of the antigen-antibody system HMW-MAA 225.28S in melanoma radioimmunodetection is reported. The results obtained in a pilot study (42 patients with 74 lesions), a multicenter trial (254 patients with 553 lesions) and a prospective study still outstanding (29 patients with 38 lesions) allow to consider this system as suitable for clinical application. F(ab')2 labelled with 99mTc gave the best results in terms of positivity. Moreover this radioisotope allows the best dosimetric conditions. The gamma energy emitted by this radionuclide is particularly convenient for conventional scintillation cameras and ECT. Very good results in terms of sensitivity (70%-85%) and especially specificity (about 100%) were achieved. Possible clinical applications of the method are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3808962

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  4 in total

1.  Detection of experimental thrombi in rabbits with an 131I-labelled fibrin-specific monoclonal antibody.

Authors:  K Z Walker; L J Milner; G J Bautovich; P Borham; A K Wood; D B Rylatt; P Martin; P G Bundesen; G R Boniface
Journal:  Eur J Nucl Med       Date:  1990

Review 2.  The role of nuclear medicine in oncology.

Authors:  H J Biersack; B Briele; A L Hotze; P Oehr; L Qian; M A Mekkawy; W J Shih
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

3.  [Initial experiences with a new monoclonal antibody in diagnosis of malignant melanomas].

Authors:  G Omlor; R Berberich; G Gross; C Alexander; G Feifel
Journal:  Langenbecks Arch Chir       Date:  1991

4.  Immunoimaging of choroidal melanoma: assessment of its diagnostic accuracy and limitations in 101 cases.

Authors:  J Scheidler; G Leinsinger; C M Kirsch; O F Scheiffarth; F H Stefani; K G Riedel
Journal:  Br J Ophthalmol       Date:  1992-08       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.